ERBB2 and cancer: It was recently approved in Japan (September 2020) as the first ADC in the world for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer that progressed on cancer chemotherapy [15].